Treatment with lysophosphatidic acid improves glomerulonephritis through the suppression of macrophage activation in a murine model of systemic lupus erythematosus

• Published in: Clinical and experimental rheumatology Vol. 42; no. 3; p. 658
• Main Authors: Nagata, Wataru, Takayama, Eiji, Nakagawa, Keiichi, Koizumi, Akiho, Ohsawa, Yukiko, Goto, Hiroyasu, Yamashiro, Aoi, Ishinoda, Yuki, Tanoue, Keiko, Kumagai, Hiroo, Oshima, Naoki, Ishizuka, Toshiaki
• Format: Journal Article
• Language: English
• Published: Italy 01.03.2024
• Subjects: Animals; Disease Models, Animal; Glomerulonephritis - drug therapy; Glomerulonephritis - prevention & control; Immunosuppressive Agents - pharmacology; Immunosuppressive Agents - therapeutic use; Lupus Erythematosus, Systemic; Lupus Nephritis - drug therapy; Lupus Nephritis - prevention & control; Lysophospholipids; Macrophage Activation; Mice; Mice, Inbred MRL lpr
• ISSN: 0392-856X; 1593-098X
• DOI: 10.55563/clinexprheumatol/ov6027

Several therapeutic agents have been developed and used for the clinical treatment of systemic lupus erythematosus (SLE). In cases where SLE is accompanied by severe organ failures, such as neuropsychiatric lupus erythematosus (NPSLE) and acute onset of lupus nephritis, the use of potent immunosuppressive drugs, such as cyclophosphamide, is necessary. However, potent immunosuppressive drugs are known to increase infection risks. Thus, the development of therapeutic agents with novel mechanisms is urgently required. Previously, we reported that treatment with lysophosphatidic acid (LPA) prevents depression-like behaviours by suppressing microglial activation in MRL/lpr mice. In this study, we examined whether the treatment with LPA improves glomerulonephritis by affecting systemic immunity in MRL/lpr mice. Eighteen-week-old MRL/lpr mice were treated with a vehicle or LPA for 3 weeks. After treatment, the glomerular inflammation and damage parameters were compared between the 2 groups. Moreover, we examined the effects of LPA on immune cells by flow cytometry using isolated splenocytes. LPA treatment in MRL/lpr mice significantly reduced the daily urinary albumin content and suppressed the CD68-positive cells and Periodic acid-Schiff (PAS)-positive areas in the glomeruli. The treatment also suppressed plasma anti-dsDNA antibodies and inflammatory cytokines in MRL/lpr mice. Although LPA did not significantly affect the total number of splenocytes, the treatment significantly reduced CD11b+Ly6G-Ly6C- cells (mature macrophages), as well as CD11b+Ly6G-Ly6C-CD68+ cells (activated mature macrophages). These results suggest that LPA may improve glomerulonephritis by suppressing macrophage activation in MRL/lpr mice.